Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Incyclinide

Drug Profile

Incyclinide

Alternative Names: Chemically modified tetracycline 3; CMT-3; COL-3; Metastat; NSC 683551

Latest Information Update: 14 Apr 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator State University of New York at Stony Brook
  • Developer CollaGenex Pharmaceuticals
  • Class Anti-inflammatories; Antiacnes; Antineoplastics; Small molecules; Tetracyclines
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acne; Acute lung injury; Cardiovascular disorders; Inflammation; Mycoses; Periodontal disorders; Rosacea

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Apr 2008 CollaGenex Pharmaceuticals has been acquired by Galderma
  • 26 Sep 2007 Discontinued - Phase-II for Rosacea in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top